Oculis to Highlight Licaminlimab at Eyecelerator @ AAO 2026 and Partner with Neuro-Ophthalmology Subspecialty Day

Impact · against what's priced in

The news provides a positive catalyst for OCS by introducing a concrete timeline for Licaminlimab data, which the market has previously ignored. While the stock is weighed down by the OCS-01 failure, the expected year-end readout for PREDICT-1 adds a new value driver alongside the already discounted Privosegtor pipeline.

OCS+0.40

Challenges what's priced in

The price assumes